Alexander Y. Mayorov

Dm. Ulyanova Street 11
Moscow, MOW 117036, Russian Federation

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.

The efficacy and safety of GP40081 (insulin aspart biphasic 30) compared with NovoMix® 30 in Type 2 diabetes patients.

Journal: Journal of comparative effectiveness research

Published: December 13, 2022

Primary hyperparathyroidism in young patients is associated with metabolic disorders: a prospective comparative study.

Primary hyperparathyroidism in young patients is associated with metabolic disorders: a prospective comparative study.

Journal: BMC endocrine disorders

Published: October 09, 2022

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings.

Journal: Journal of diabetes science and technology

Published: March 29, 2022

The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities

The National Consensus statement on the management of adult patients with non-alcoholic fatty liver disease and main comorbidities

Journal: Terapevticheskii arkhiv

Published: December 20, 2021

Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.

Clinical Pharmacology of Insulin Aspart Biosimilar GP40071: Pharmacokinetic/Pharmacodynamic Comparability in Hyperinsulinemic Euglycemic Clamp Procedure.

Journal: Clinical pharmacology in drug development

Published: November 12, 2021

Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid® Penfill®) in Type 1 diabetes mellitus.

Safety and efficacy of GP40071 compared with originator insulin aspart (NovoRapid® Penfill®) in Type 1 diabetes mellitus.

Journal: Journal of comparative effectiveness research

Published: April 30, 2021

Identifying the unmet needs of individuals with Type 2 diabetes: an international web-based survey.

Identifying the unmet needs of individuals with Type 2 diabetes: an international web-based survey.

Journal: Journal of comparative effectiveness research

Published: March 26, 2021

The prospects for the creation of the National Center for Personalized Medicine of Endocrine Diseases

The prospects for the creation of the National Center for Personalized Medicine of Endocrine Diseases

Journal: Problemy endokrinologii

Published: January 26, 2021

Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features

Diabetes mellitus and chronic liver diseases. Literature review (part 2): treatment features

Journal: Terapevticheskii arkhiv

Published: April 16, 2020

Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis

Diabetes mellitus and chronic liver diseases. Part 1: general mechanisms of etiology and pathogenesis

Journal: Terapevticheskii arkhiv

Published: April 16, 2020

Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial.

Safety and efficacy of GP40061 compared with originator insulin glargine (Lantus®): a randomized open-label clinical trial.

Journal: Journal of comparative effectiveness research

Published: February 07, 2020

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range.

Journal: Diabetes care

Published: June 10, 2019

Showing 1-12 of 18

Last Updated: 09/26/2026